Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial

Open access
Ratziu, V., de Guevara, L., Safadi, R., Poordad, F., Fuster, F., Flores-Figueroa, J., Arrese, M., Fracanzani, Anna L., Ben Bashat, D., Lackner, K., Gorfine, T., Kadosh, S., Oren, R., Halperin, M., Hayardeny, L., Loomba, R., Friedman, S., the ARREST investigator study group, Abdelmalek, M., Angelico, F., Angelico, M., Arancibia, J. P., Bardou-Jacquet, E., Barrera, F., Barish, C. F., Baruch, Y., Ben-Ari, Z., Berg, T., Bourliere, M., Boursier, J., Broide, E., Carmiel, M., Denham, D. S., Di Cesare, L., Dumitrascu, D. L., Francis, A., Gawrieh, S., González- Huezo, M. S., Hillon, P., Iracheta, A., Kayali, Z., Kupcinskas, L., Lau, G., Serfaty, L., Le Cleach, A., Loguercio, C., Manns, M., Martinez Saldivar, B. I., Mena, E. A., Morales Garza, L. A., Neutel, J. M., Nikoleishvili, L., Noureddin, M., Pais, R., Paredes, A. H., Paredes, M., Peters Watkins, R., Picardi, A., Pirisi, M., Jofre, G. P., Preotescu, L., Saadi, T., Samuel, D., Sánchez Avila, J. F., Schiefke, I., Shibolet, O., Siddiqui, M. S., Torres-Mendoza, G., Trotter, J. F., Tsai, E., Verna, E. C., Zuckerman, E., Zur, D., Sanyal, Arun J. · 2021 · Nature Medicine

Abstract

Nonalcoholic steatohepatitis (NASH), a chronic liver disease without an approved therapy, is associated with lipotoxicity and insulin resistance and is a major cause of cirrhosis and hepatocellular carcinoma. Aramchol, a partial inhibitor of hepatic stearoyl-CoA desaturase (SCD1) improved steatohepatitis and fibrosis in rodents and reduced steatosis in an early clinical trial. ARREST, a 52-week, double-blind, placebo-controlled, phase 2b trial randomized 247 patients with NASH (n = 101, n = 98 and n = 48 in the Aramchol 400 mg, 600 mg and placebo arms, respectively; NCT02279524 ). The primary end point was a decrease in hepatic triglycerides by magnetic resonance spectroscopy at 52 weeks with a dose of 600 mg of Aramchol. Key secondary end points included liver histology and alanine aminotransferase (ALT). Aramchol 600 mg produced a placebo-corrected decrease in liver triglycerides without meeting the prespecified significance (-3.1, 95% confidence interval (CI) -6.4 to 0.2, P = 0.066), precluding further formal statistical analysis. NASH resolution without worsening fibrosis was achieved in 16.7% (13 out of 78) of Aramchol 600 mg versus 5% (2 out of 40) of the placebo arm (odds ratio (OR) = 4.74, 95% CI = 0.99 to 22.7) and fibrosis improvement by ≥1 stage without worsening NASH in 29.5% versus 17.5% (OR = 1.88, 95% CI = 0.7 to 5.0), respectively. The placebo-corrected decrease in ALT for 600 mg was -29.1 IU l-1 (95% CI = -41.6 to -16.5). Early termination due to adverse events (AEs) was <5%, and Aramchol 600 and 400 mg were safe, well tolerated and without imbalance in serious or severe AEs between arms. Although the primary end point of a reduction in liver fat did not meet the prespecified significance level with Aramchol 600 mg, the observed safety and changes in liver histology and enzymes provide a rationale for SCD1 modulation as a promising therapy for NASH and fibrosis and are being evaluated in an ongoing phase 3 program.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-021-01495-3

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 223

Metadata

Authors
Ratziu, V., de Guevara, L., Safadi, R., Poordad, F., Fuster, F., Flores-Figueroa, J., Arrese, M., Fracanzani, A. L., Ben Bashat, D., Lackner, K., Gorfine, T., Kadosh, S., Oren, R., Halperin, M., Hayardeny, L., Loomba, R., Friedman, S., the ARREST investigator study group, Abdelmalek, M., Angelico, F., Angelico, M., Arancibia, J. P., Bardou-Jacquet, E., Barrera, F., Barish, C. F., Baruch, Y., Ben-Ari, Z., Berg, T., Bourliere, M., Boursier, J., Broide, E., Carmiel, M., Denham, D. S., Di Cesare, L., Dumitrascu, D. L., Francis, A., Gawrieh, S., González- Huezo, M. S., Hillon, P., Iracheta, A., Kayali, Z., Kupcinskas, L., Lau, G., Serfaty, L., Le Cleach, A., Loguercio, C., Manns, M., Martinez Saldivar, B. I., Mena, E. A., Morales Garza, L. A., Neutel, J. M., Nikoleishvili, L., Noureddin, M., Pais, R., Paredes, A. H., Paredes, M., Peters Watkins, R., Picardi, A., Pirisi, M., Jofre, G. P., Preotescu, L., Saadi, T., Samuel, D., Sánchez Avila, J. F., Schiefke, I., Shibolet, O., Siddiqui, M. S., Torres-Mendoza, G., Trotter, J. F., Tsai, E., Verna, E. C., Zuckerman, E., Zur, D., & Sanyal, A. J.
Affiliations
  • Inserm (FR)
  • Hadassah Medical Center (IL)
  • The University of Texas at San Antonio Health Science Center (US)
  • Pontificia Universidad Católica de Chile (CL)
  • University of Milan (IT)
  • Medical University of Graz (AT)
  • Galmed Pharmaceuticals (Israel) (IL)
  • University of California San Diego (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • Duke Medical Center (US)
  • Policlinico Umberto I (IT)
  • Hospital Clínico de la Universidad de Chile (CL)
  • Rambam Health Care Campus (IL)
  • Sheba Medical Center (IL)
  • Hôpital Saint Joseph (FR)
  • Centre Hospitalier Universitaire d'Angers (FR)
  • Assaf Harofeh Medical Center (IL)
  • Clinical Trials of Texas (US)
  • Holy Family Hospital Nazareth (IL)
  • Indiana University Indianapolis (US)
  • CHU Dijon Bourgogne (FR)
  • Inland Empire Liver Foundation (US)
  • Lithuanian University of Health Sciences (LT)
  • Humanity & Health (CN)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • University of Campania "Luigi Vanvitelli" (IT)
  • Medizinische Hochschule Hannover (DE)
  • California Liver Research Institute (US)
  • Orange County Research Center (US)
  • Cedars-Sinai Medical Center (US)
  • Brooke Army Medical Center (US)
  • Profil Institute for Clinical Research (US)
  • Azienda Ospedaliero Universitaria Maggiore della Carita (IT)
  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
  • Tel Aviv Sourasky Medical Center (IL)
  • Virginia Commonwealth University (US)
  • Texas Liver Institute (US)
  • Columbia University Irving Medical Center (US)
  • Carmel Medical Center (IL)
Corresponding author
Ratziu, V.
Venue
Nature Medicine
Published
2021-10
Volume
27
Issue
10
Pages
1825-1835
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3203570622
Cited by
222
References
51
Citations by year
2026: 21 · 2025: 48 · 2024: 56 · 2023: 57 · 2022: 36 · 2021: 3
FWCI
27.38
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • HAL (submittedVersion, other-oa)
  • Lithuanian University of Health Sciences (submittedVersion)
Funders
Galmed Pharmaceuticals, Ltd.
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
nonalcoholic steatohepatitis, hepatic triglycerides, liver fibrosis, NASH resolution, alanine aminotransferase, steatosis, liver histopathology, drug safety and tolerability, magnetic resonance spectroscopy, insulin resistance, lipotoxicity
MeSH terms
Alanine Transaminase, Biopsy, Cholic Acids, Double-Blind Method, Female, Humans, Liver, Male, Middle Aged, Magnetic Resonance Spectroscopy, Stearoyl-CoA Desaturase, Triglycerides, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. https://app.cochat.ai/papers/10.1038/s41591-021-01495-3
The paper
Ratziu, V., de Guevara, L., Safadi, R., Poordad, F., Fuster, F., Flores-Figueroa, J., Arrese, M., Fracanzani, A. L., Ben Bashat, D., Lackner, K., Gorfine, T., Kadosh, S., Oren, R., Halperin, M., Hayardeny, L., Loomba, R., Friedman, S., the ARREST investigator study group, Abdelmalek, M., . . . Sanyal, A. J. (2021). Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nature Medicine. https://doi.org/10.1038/s41591-021-01495-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.